Slide 1: Proven Ability In Life Sciences
Proven Ability In Life Sciences November 14, 2025 To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Scrip code: SEQUENT Subject: Investor Pr
Slide 2: Investor Presentation Q2 FY26
INVESTOR PRESENTATION Q2 FY26 SEQUENT SCIENTIFIC LIMITED 14th Nov 2025
Slide 3: Steadfast commitment to improvement in business fundamentals
Steadfast commitment to improvement in business fundamentals “The results of Q4 FY 25-26 and first half FY 25-26 reinforce the transformational journey undertaken by the company. Revenue, margins and profits have continued to show healthy growth on the back of new product introductions, superior pro
Slide 4: Sequent + Viyash: Combined Q2 FY26 Performance Highlights
All values in ₹ Mn Sequent + Viyash : Combined Q2 FY26 Performance Highlights Net Debt to LTM Revenues EBITDA1 EBITDA margin EBITDA1 ₹8,521 ₹1,890 22.2% 0.7x Million Million +16 % +76% +750 bps 1.4x in Q2 YoY YoY YoY FY25 3 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Source:
Slide 5: Sequent + Viyash: Combined H1 FY26 Performance Highlights
All values in ₹ Mn Sequent + Viyash : Combined H1 FY26 Performance Highlights Net Debt to LTM Revenues EBITDA1 EBITDA margin EBITDA1 ₹16,462 ₹3,810 19.3% 0.7x Million Million +12.5 % +48 % +460 bps 1.4x in H1 YoY YoY YoY FY25 4 Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs Sour
Slide 6: SeQuent Q2FY26 Performance Update
SeQuent Q2FY26 Performance Update
Slide 7: Sequent: Strong profitable business growth continues in Q2FY26
Sequent: Strong profitable business growth continues in Q2FY26 All values in ₹ Mn Revenues EBITDA1 EBITDA1 margin PAT ₹4,240 ₹657 15.5% ₹ 196 Million Million Million +15.0% +47.0% +330 bps +200% YoY YoY YoY YoY 6 1. EBITDA Adjustment for ESOP and foreign currency fluctuation
Slide 8: Sequent: Strong profitable business growth continues in H1 FY26
Sequent: Strong profitable business growth continues in H1 FY26 All values in ₹ Mn Revenues EBITDA1 EBITDA1 margin PAT ₹4,240 ₹8,654 ₹1,259 ₹657 14.5% ₹ 372 Million Million Million +14.0% +35.4 % +220 bps +140 % YoY YoY YoY YoY 7 1. EBITDA Adjustment for ESOP and foreign currency fluctuation
Slide 9: Sequent: Broad based revenue growth across all businesses
Sequent : Broad based revenue growth across all businesses All values in ₹ Mn Revenue Distribution Q2 FY26 Q2 FY25 YoY Gr% Q1 FY26 QnQ Gr% H1 FY26 H1 FY25 YoY Gr% Formulations 3,351 2,836 18% 3,383 -1% 6,734 5,837 15% Europe 1,520 1,335 14% 1,640 -7% 3,159 2,910 9% Emerging Markets 1,469 1,160 27% 1
Slide 10: SeQuent: Q2FY26 Business Performance
SeQuent: Q2FY26 Business Performance All values in ₹ Mn Europe: Significant growth in Spain with good exports performance 1,000+ FDFs Emerging Markets: Formulations ▪ Launched Tulaject in Brazil & received MA for Mexico market 90+ ▪ R&D infrastructure expanded Countries India: Business beginning to
Slide 11: Sequent Consolidated Financials
Sequent Consolidated Financials All values in ₹ Mn Q2 Q2 Grw YoY Q1 Grw QnQ H1 H1 Grw YoY Particulars FY26 FY25 % FY26 % FY26 FY25 % Revenue from Operations 4,240 3,686 15.0% 4,414 -3.9% 8,654 7,589 14.0% Material Consumption (2,131) (1,953) (2,345) (4,477) (4,096) Gross Margin 2,109 1,734 21.6% 2,0
Slide 12: Viyash: Business Update
Viyash Viyash: Business Update
Slide 13: Viyash: Q2FY26 Business Performance
Viyash: Q2FY26 Business Performance Revenues EBITDA1 EBITDA1 margin PAT ₹4,281 ₹1,233 28.8% ₹533 Million Million Million 1149 Q2 17.8% 96% YoY YoY bps FY25 YoY Loss (82mn) 12 Note: 1. Viyash EBITDA is adjusted for ESOP costs
Slide 14: Viyash: Q2 FY26 Key growth drivers
Viyash: Q2 FY26 Key growth drivers New product launches Focus on CDMO business Improved product mix Network optimisation for better efficiencies Backward and Forward integration 13
Slide 15: Viyash: H1FY26 Business Performance
Viyash: H1FY26 Business Performance Revenues EBITDA1 EBITDA1 margin PAT ₹7,808 ₹1,921 24.6% ₹726 Million Million Million 741 H1 11.0% 58.9% YoY YoY bps FY25 YoY Loss (94mn) 14 Note: 1. Viyash EBITDA is adjusted for ESOP costs
Slide 16: Viyash Financial Performance
Viyash Financial Performance All values in ₹ Mn Q2 Q2 Grw Q1 Grw H1 H1 Grw Particulars FY 25 FY26 FY25 YoY% FY26 QnQ % FY26 FY25 YoY o Healthy revenue growth. Q2FY26 Revenue from Operations 4,281 3,632 18% 3,527 21% 7,808 7,032 11% 14,580 revenue grew by 18% YoY. H1FY26 Material Consumption (1,667)
Slide 17: Key updates from Q2 FY26
Key updates from Q2 FY26 Facility Inspections Regulatory Approvals Launches 4 Regulatory Audits 2APIs: (USDMF-1 ; 2 FDFs (US) 56 Customer audits EDQM-1 2 APIs 1 US FDA EIR Products Filed Validations Completed R&D Pipeline 9 Filings – SFDA(3), 3 APIs 16+ Products EDQM (1) TGA (1), EDMF (2), WHO (1),
Slide 18: Merger Update
Merger Update bo
Slide 19: Q2FY26: Combined business performance
Q2FY26: Combined business performance Q2 FY26 YoY Growth % SeQuent Combined (For the quarter) (Combined) Revenue 4,281 4,240 8,521 16.3% (INR Mn) EBITDA1 1,233 657 1,890 76% (INR Mn) EBITDA Margin % 28.8% 15.5% 22.2% +750 bps Net Debt to LTM 0.08x 1.7x 0.7x EBITDA 18 Notes: 1. EBITDA for Viyash and
Slide 20: Combined P&L – Snapshot
Combined P&L – Snapshot Viyash SeQuent Combined Particulars Key Notes : FY25 H1 FY26 FY25 H1 FY26 FY25 H1 FY26 Revenue from Operations 14,580 7,808 15,514 8,654 30,094 16,462 ESOP cost, Exceptional items and Material Consumption (6,608) (3,147) (8,119) (4,477) (14,727) (7,624) amortization of acquis
Slide 21: Merger – Process Update
Merger – Process Update Merger process status update • CCI approval and Stock Exchange clearance received • NCLT approval order reserved on Oct 31, 2025; pronouncement expected soon • Focus on synergy realization for next 12 months • The process is well on track as per estimated timelines 20
Slide 22: Synergy Update
Synergy Update Area Key Ideation Action Items Progress • R&D teams to be co-located; to work API R&D fully integrated leading to collaboratively on NPD & cost accelerated development • 4 New animal health products Regulatory filing in R&D improvement developed/validated progress • QA & Testing to be
Slide 23: New production block commissioned in record time
New production block commissioned in record time New production block created in short time to improve capacity, productivity and cost of Sequent products One large volume Sequent API validated & filing under progress 22
Slide 24: For details, feel free to contact
For details, feel free to contact: Yoshita Vora Abhishek Singhal Company Secretary Investor Relations Consultant +91 22 4111 4777 abhishek@arunya.co.in investorrelations@sequent.in Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Sh
Slide 25: Thank You
Thank You